» Articles » PMID: 24950695

Silencing of CCR2 in Myocarditis

Abstract

Background: Myocarditis is characterized by inflammatory cell infiltration of the heart and subsequent deterioration of cardiac function. Monocytes are the most prominent population of accumulating leucocytes. We investigated whether in vivo administration of nanoparticle-encapsulated siRNA targeting chemokine (C-C motif) receptor 2 (CCR2)-a chemokine receptor crucial for leucocyte migration in humans and mice--reduces inflammation in autoimmune myocarditis.

Methods And Results: In myocardium of patients with myocarditis, CCL2 mRNA levels and CCR2(+) cells increased (P < 0.05), motivating us to pursue CCR2 silencing. Flow cytometric analysis showed that siRNA silencing of CCR2 (siCCR2) reduced the number of Ly6C(high) monocytes in hearts of mice with acute autoimmune myocarditis by 69% (P < 0.05), corroborated by histological assessment. The nanoparticle-delivered siRNA was not only active in monocytes but also in bone marrow haematopoietic progenitor cells. Treatment with siCCR2 reduced the migration of bone marrow granulocyte macrophage progenitors into the blood. Cellular magnetic resonance imaging (MRI) after injection of macrophage-avid magnetic nanoparticles detected myocarditis and therapeutic effects of RNAi non-invasively. Mice with acute myocarditis showed enhanced macrophage MRI contrast, which was prevented by siCCR2 (P < 0.05). Follow-up MRI volumetry revealed that siCCR2 treatment improved ejection fraction (P < 0.05 vs. control siRNA-treated mice).

Conclusion: This study highlights the importance of CCR2 in the pathogenesis of myocarditis. In addition, we show that siCCR2 affects leucocyte progenitor trafficking. The data also point to a novel therapeutic strategy for the treatment of myocarditis.

Citing Articles

Macrophage-derived SPP1 exacerbate myocardial injury by interacting with fibroblasts in viral myocarditis.

Duan X, Zhang L, Liu K, Guo K, You Y, Jia H Biol Direct. 2025; 20(1):30.

PMID: 40087693 DOI: 10.1186/s13062-025-00621-2.


Assessing customized multivalent chemokine-binding peptide treatment in a murine model of coxsackievirus B3 myocarditis.

Kelm N, Kespohl M, Smagurauskaite G, Vales S, Karuppanan K, Mburu P Basic Res Cardiol. 2025; .

PMID: 40009121 DOI: 10.1007/s00395-025-01098-w.


The cellular and molecular cardiac tissue responses in human inflammatory cardiomyopathies after SARS-CoV-2 infection and COVID-19 vaccination.

Maatz H, Lindberg E, Adami E, Lopez-Anguita N, Perdomo-Sabogal A, Cocera Ortega L Nat Cardiovasc Res. 2025; .

PMID: 39994453 DOI: 10.1038/s44161-025-00612-6.


Cellular Immunology of Myocarditis: Lights and Shades-A Literature Review.

Vicenzetto C, Giordani A, Menghi C, Baritussio A, Scognamiglio F, Pontara E Cells. 2025; 13(24.

PMID: 39768171 PMC: 11674465. DOI: 10.3390/cells13242082.


At the heart of inflammation: Unravelling cardiac resident macrophage biology.

Liao Y, Zhu L J Cell Mol Med. 2024; 28(17):e70050.

PMID: 39223947 PMC: 11369210. DOI: 10.1111/jcmm.70050.


References
1.
Serbina N, Pamer E . Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006; 7(3):311-7. DOI: 10.1038/ni1309. View

2.
Si Y, Tsou C, Croft K, Charo I . CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J Clin Invest. 2010; 120(4):1192-203. PMC: 2846049. DOI: 10.1172/JCI40310. View

3.
Nahrendorf M, Sosnovik D, Waterman P, Swirski F, Pande A, Aikawa E . Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res. 2007; 100(8):1218-25. DOI: 10.1161/01.RES.0000265064.46075.31. View

4.
Blyszczuk P, Valaperti A, Eriksson U . Future therapeutic strategies in inflammatory cardiomyopathy: insights from the experimental autoimmune myocarditis model. Cardiovasc Hematol Disord Drug Targets. 2008; 8(4):313-21. DOI: 10.2174/1871529x10808040313. View

5.
Leuschner F, Katus H, Kaya Z . Autoimmune myocarditis: past, present and future. J Autoimmun. 2009; 33(3-4):282-9. DOI: 10.1016/j.jaut.2009.07.009. View